DE60330256D1 - Bakteriophagen-vermittelte immunisierung gegen hepatitis - Google Patents

Bakteriophagen-vermittelte immunisierung gegen hepatitis

Info

Publication number
DE60330256D1
DE60330256D1 DE60330256T DE60330256T DE60330256D1 DE 60330256 D1 DE60330256 D1 DE 60330256D1 DE 60330256 T DE60330256 T DE 60330256T DE 60330256 T DE60330256 T DE 60330256T DE 60330256 D1 DE60330256 D1 DE 60330256D1
Authority
DE
Germany
Prior art keywords
bacteriophage
immunization against
against hepatitis
mediated immunization
bacteriophage mediated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60330256T
Other languages
English (en)
Inventor
John Bernard March
Jason Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BigDNA Ltd
Original Assignee
BigDNA Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BigDNA Ltd filed Critical BigDNA Ltd
Application granted granted Critical
Publication of DE60330256D1 publication Critical patent/DE60330256D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
DE60330256T 2002-10-02 2003-10-02 Bakteriophagen-vermittelte immunisierung gegen hepatitis Expired - Lifetime DE60330256D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0222824.5A GB0222824D0 (en) 2002-10-02 2002-10-02 Bacteriophage-mediated immunisation II
PCT/GB2003/004267 WO2004030694A1 (en) 2002-10-02 2003-10-02 Bacteriophage-mediated immunisation against hepatitis

Publications (1)

Publication Number Publication Date
DE60330256D1 true DE60330256D1 (de) 2010-01-07

Family

ID=9945160

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60330256T Expired - Lifetime DE60330256D1 (de) 2002-10-02 2003-10-02 Bakteriophagen-vermittelte immunisierung gegen hepatitis

Country Status (12)

Country Link
US (1) US7910110B2 (de)
EP (1) EP1545594B1 (de)
JP (1) JP4535874B2 (de)
AT (1) ATE449611T1 (de)
AU (1) AU2003278306A1 (de)
DE (1) DE60330256D1 (de)
DK (1) DK1545594T3 (de)
ES (1) ES2334994T3 (de)
GB (1) GB0222824D0 (de)
PT (1) PT1545594E (de)
SI (1) SI1545594T1 (de)
WO (1) WO2004030694A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0808780D0 (en) * 2008-05-15 2008-06-18 Big Dna Ltd Fish vaccines
TWI547562B (zh) 2011-08-05 2016-09-01 神經噬菌體製藥股份有限公司 純質絲狀噬菌體及其生產方法
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU576907B2 (en) 1984-11-01 1988-09-08 American Home Products Corporation Oral vaccines comprising live recombinant adenoviruses
US5736388A (en) 1994-12-30 1998-04-07 Chada; Sunil Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
WO1998005344A1 (en) 1996-08-05 1998-02-12 Brigham And Women's Hospital, Inc. Bacteriophage-mediated gene therapy
FR2760193B1 (fr) 1997-02-28 1999-05-28 Transgene Sa Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
EP0956050A1 (de) * 1997-06-12 1999-11-17 Transgene S.A. Komplexe lipide zur übertragung von wenigstens einer therapeutisch wirksamen verbindung, insbesonderes ein polynukleotid, in einer zielzelle
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
CA2329908A1 (en) * 1998-04-24 1999-11-04 The Regents Of The University Of California Targeted gene delivery to cells by filamentous bacteriophage
BR0010322A (pt) * 1999-05-06 2002-04-09 Univ Wake Forest Vetor de expressão, vacina e seu método de uso para eliciar uma resposta imune dirigida contra um antìgeno em um mamìfero
WO2001014579A2 (en) 1999-08-26 2001-03-01 Vion Pharmaceuticals, Inc. Compositions and methods for delivery of an agent using attenuated salmonella containing phage
GB0107319D0 (en) * 2001-03-23 2001-05-16 Moredun Res Inst Bacteriophage-mediated immunisation
WO2004050829A2 (en) 2002-08-20 2004-06-17 Aeras Global Tuberculosis Vaccine Foundation Recombinant double-stranded rna phage, and use of the same

Also Published As

Publication number Publication date
EP1545594A1 (de) 2005-06-29
PT1545594E (pt) 2010-01-19
EP1545594B1 (de) 2009-11-25
US20090010960A1 (en) 2009-01-08
US7910110B2 (en) 2011-03-22
WO2004030694A1 (en) 2004-04-15
SI1545594T1 (sl) 2010-05-31
JP2006503860A (ja) 2006-02-02
ATE449611T1 (de) 2009-12-15
JP4535874B2 (ja) 2010-09-01
ES2334994T3 (es) 2010-03-18
AU2003278306A1 (en) 2004-04-23
DK1545594T3 (da) 2010-03-08
GB0222824D0 (en) 2002-11-06

Similar Documents

Publication Publication Date Title
CY1111286T1 (el) Ανοσοποιηση διαμεσολαβουμενη απο βακτηριοφαγα
FR20C1016I1 (de)
DE60142689D1 (de) Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen
EP3552622A3 (de) Priming einer immunantwort
ATE523205T1 (de) Prime-boost-impfstoffe gegen malaria
CY1105616T1 (el) ΠΕΠΤΙΔΙΑ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TGFβ1
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
ATE433491T1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
IL210378A0 (en) Tumor associated antigen, peptides thereof, and use of same as ati-tumor vaccines
ATE551048T1 (de) Proteinhydrolysate enthaltende kosmetische zusammensetzungen
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
ATE460176T1 (de) Mikrosomvakzin
TW200641126A (en) N protein mutants of porcine reproductive and respiratory syndrome virus
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
ATE493497T1 (de) Verfahren zur herstellung von oligopeptiden
MY144766A (en) Plant virus coat fusion proteins with gdf8 epitopes and vaccines thereof
DE60330256D1 (de) Bakteriophagen-vermittelte immunisierung gegen hepatitis
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
DK1368372T3 (da) Peptid med affinitet til det virale gp120-protein samt anvendelse deraf
EP1499349A4 (de) Rekombinante hybrid-allergenkonstrukte mit verringerter allergenität unter beibehaltung der immunogenität des natürlichen allergens
NZ515041A (en) Nucleic acid immunization
UY30602A1 (es) Mutante de un pestivirus, vacuna y aplicaciones
ATE467421T1 (de) Cytokine und cytokinrezeptoren mit reduzierter immunogenität
ES2531098T3 (es) Nuevos mutantes de proteína de superficie del antígeno de superficie del virus HVB de Hepatitis B (HBsAg)
ATE192163T1 (de) Peptide, analoge und ihre mischungen zur detektion und erzeugung von antikörpern gegen die e1 und e2 proteine des rubella virus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition